- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03246022
Characteristics of Obstructive Sleep Apnea Syndrome Related Hypertension and the Effect of Continuous Positive Airway Pressure Treatment on Blood Pressure
Huai'an First People's Hospital
Obstructive sleep apnea syndrome (OSAS) causes nocturnal chronic intermittent hypoxia (CIH) that contributes to the development of hypertension. CIH profiles, including the its length, speed and intensity were widely different in individuals. Until recently, the influence of OSAS-related IH profiles on hypertension development has not been fully explored. The present study aimed to investigate the effects of different CIH properties on blood pressure (BP) and short-term blood pressure variability (BPV) in severe OSAS patients.
Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. In theory, CPAP maintains upper airway patency and preserves ventilation, thereby inhibits the chain reaction over activation of the sympathetic nervous system and blood pressure regulating mechanism, thus CPAP treatment have adequate scientific basis to cause a substantial reduction arterial blood pressure, but controlled studies showed either no effect or only a minor decrease in arterial blood pressure by 1.4 and 2.5 mmHg respectively.The current, which type of combination of hypertension OSA patients can obtain the best antihypertensive benefit from CPAP therapy is still under debate.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nocturnal BP was continuously monitored via measurement of pulse transmit time (PTT). The value of apnea-related systolic BP elevation (△BP) was used to reflect short-term BPV. Beat-to-beat RR interval data were incorporated in polysomnography for heart rate variability analysis. LF/HF band ratio was compared between two groups which used to reflect sympatho-vagal balance. The length of the desaturation event was measured to the nearest 0.5 second (△t). The fall in SpO2 during apnea was calculated as the gap from start of the desaturation to the nadir of the desaturation. The rate of fall in SpO2 was counted as the change in the percentage of SpO2 per second (△SpO2 /△t) and expressed as oxygen desaturation rate (ODR), which reflected the speed and efficacy of oxygen desaturation during an apnea event. One hundred and two severe OSAS subjects were divided into two groups according to the their median ODR: faster ODR and slower ODR.
In addtion,patient were categorized into three groups: Group l: systolic blood pressure index was less than 30% of AHI; Group 2: systolic blood pressure index was less than 60% but more than 30%; Group 3: systolic blood pressure index is more than 60% of AHI. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated. The main purpose of study is to confirm the OSA with hypertension and OSA secondary hypertension are two different concepts. Basis for the clinical treatment, the former, CPAP might have no effect or only a minor decrease in arterial blood pressure, while the latter CPAP treatment might achieve significant antihypertensive effect.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Huai'an, Jiangsu, China, 223300
- Department Of Respiratory Medicine,Huai'an First People's Hospital,Nanjing Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- age between 18 to 70 yrs;
- newly diagnosed OSAS without treatment;
Description
Inclusion Criteria:
- BP≤180/110mmHg,but≥140/90mmHg
- without taking oral antihypertensive drugs. Exclusion criteria.
(1) patients who had been hospitalized for cardiac or respiratory exacerbation<6wk prior to recruiting; (2) with autonomic nervous system diseases or endocrine disorders which might influence BP; (3) unwilling to participate in the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group l
SBP index was less than 30% of AHI
|
Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical.
The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups.
Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
|
Group 2
SBP index was less than 60% but more than 30%
|
Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical.
The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups.
Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
awake systolic blood pressure(SBP)changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
as the mean systolic blood pressure measurements during a supine resting period of 1 0minute at awake state
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
sleep systolic blood pressure(SBP)changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
as the average of systolic blood pressure values during sleep
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
sympathetic-parasympathetic nerve balance changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
Studies using spectral analysis of R-R intervals have reported that the power spectrum contains both low-frequency(LF,0.04-0.15
Hz)and high-frequency peaks(HF,0.15-0.5Hz),HF
power reflects parasympathetic activity,whereas LF power primarily reflects sympathetic activity with a parasympathetic component.The LF-to-HF ratio(LF/HF)is commonly regarded as an index of sympathovagal balance
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
renin-angiotensin-aldosterone systemchanges
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
as the levels of plasma angiotension ⅰ( Ang I) and angiotension ⅱ( Ang ⅱ) before and after CPAP treatment
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
AHI changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
the combined number of apnea and hypopnea episodes per hour of sleep
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
TST90 changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
percentage of sleep time with oxygen saturation < 90%
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
oxygen desaturation index(ODI) changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
oxygen desaturation index
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
event-related systolic blood pressure elevation (△SBP) changes
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
as the gap between the peak value of postapneic SBP and lowest SBP during a obstructive respiratory event
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
systolic blood pressure(SBP)index
Time Frame: change from Baseline Systolic Blood Pressure at 2 weeks
|
as the number of △SBP>10mmHg per hour of sleep time.
|
change from Baseline Systolic Blood Pressure at 2 weeks
|
Desaturation rate
Time Frame: one night
|
The rate of fall in SpO2 was counted as the change in the percentage of SpO2 per second during apnea
|
one night
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Zili Meng, Master, Department Of Respiratory Medicine,Huai'an First People's Hospital,Nanjing Medical University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Huaian First People's Hospital
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension Secondary
-
University GhentCompletedPrimary Hypertension | Secondary HypertensionBelgium
-
First Affiliated Hospital of Chengdu Medical CollegeRecruitingPrimary Aldosteronism | Resistant Hypertension | Secondary Hypertension | Secondary Hypertension to Endocrine DisordersChina
-
National Taiwan University HospitalWithdrawnPrimary and Secondary Pulmonary HypertensionTaiwan
-
Wenzhou Medical UniversityCompleted
-
Northwell HealthChildren's Hospital of PhiladelphiaCompletedHypertension Secondary to Kidney TransplantUnited States
-
Wake Forest University Health SciencesCompletedHypertension SecondaryUnited States
-
All India Institute of Medical Sciences, New DelhiUnknownPulmonary Hypertension Secondary to Lung Disease and/or HypoxiaIndia
-
Universiti Sains MalaysiaCompleted
-
Assiut UniversityUnknownCOPD | Pulmonary Hypertension Secondary
-
Tampere UniversityFinnish Cultural Foundation; Sigrid Jusélius Foundation; Päivikki and Sakari... and other collaboratorsRecruitingRenal Insufficiency | Aortic Stenosis | Primary Hypertension | Secondary HypertensionFinland
Clinical Trials on continuous positive airway pressure
-
University Hospital, GrenobleResMed; Société francophone de pneumologie de langue francaiseCompletedType 1 Diabetes | Sleep Apnea SyndromeFrance
-
University Hospital, MontpellierCompletedCoronary Artery Disease | Sleep Apnea SyndromeFrance
-
Sanjay R PatelBeth Israel Deaconess Medical Center; National Institutes of Health (NIH); Brigham...CompletedSleep Apnea, Obstructive | Diabetes MellitusUnited States
-
Fisher and Paykel HealthcareHelios Klinik AmbrockCompleted
-
Chinese Pulmonary Vascular Disease Research GroupCompletedObstructive Sleep Apnea | Coronary Heart DiseaseChina
-
Poitiers University HospitalCompletedObstructive Sleep Apnea Syndromes
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University Hospital, MontpellierUnknownObstructive Sleep Apnea Syndrome | Brain InfarctionFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedSleep Apnea, Obstructive | Fatigue | SarcoidosisItaly
-
Eileen R. ChasensCompletedSleep Apnea, Obstructive | Diabetes Mellitus, Type 2United States